Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parathyroid hormone does not inhibit platelet aggregation.

C Leithner, J Kovarik, H Sinzinger

    Lancet (London, England)
    |February 18, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Higher versus lower mean arterial blood pressure after cardiac arrest and resuscitation (MAP-CARE): A protocol for a randomized clinical trial.

    Acta anaesthesiologica Scandinavica·2025
    Same author

    Fever management with or without a temperature control device after out-of-hospital cardiac arrest and resuscitation (TEMP-CARE): A study protocol for a randomized clinical trial.

    Acta anaesthesiologica Scandinavica·2025
    Same author

    Sedation, temperature and pressure after cardiac arrest and resuscitation-The STEPCARE trial: A statistical analysis plan.

    Acta anaesthesiologica Scandinavica·2025
    Same author

    Continuous deep sedation versus minimal sedation after cardiac arrest and resuscitation (SED-CARE): A protocol for a randomized clinical trial.

    Acta anaesthesiologica Scandinavica·2025
    Same author

    EEG for good outcome prediction after cardiac arrest: A multicentre cohort study.

    Resuscitation·2024
    Same author

    [Postcardiac arrest treatment guide].

    Medizinische Klinik, Intensivmedizin und Notfallmedizin·2019
    Same journal

    Assisted dying and the silencing of medicine's next generation.

    Lancet (London, England)·2026
    Same journal

    Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

    Lancet (London, England)·2026
    Same journal

    Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

    Lancet (London, England)·2026
    Same journal

    [<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

    Lancet (London, England)·2026
    Same journal

    Research priorities for characterising Bundibugyo virus.

    Lancet (London, England)·2026
    Same journal

    Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

    Lancet (London, England)·2026
    See all related articles

    Parathyroid hormone (PTH) does not appear to cause platelet dysfunction in uremia. Studies showed synthetic PTH fragments and bovine PTH did not affect platelet aggregation, challenging the uremic toxin theory.

    Area of Science:

    • Nephrology
    • Hematology
    • Endocrinology

    Background:

    • Uremia is associated with platelet dysfunction and bleeding tendencies.
    • Parathyroid hormone (PTH) has been proposed as a potential uremic toxin contributing to these issues.

    Purpose of the Study:

    • To investigate the role of parathyroid hormone (PTH) in uremic platelet dysfunction.
    • To determine if synthetic PTH fragments or bovine PTH affect platelet aggregation.

    Main Methods:

    • Testing the effects of synthetic human PTH fragments and synthetic bovine PTH on ADP- and collagen-induced platelet aggregation.
    • Comparing results with platelet aggregation studies in patients with primary hyperparathyroidism before and after parathyroid gland surgery.

    Main Results:

    Related Experiment Videos

    • Synthetic PTH compounds did not inhibit platelet aggregation, even at high concentrations.
    • Extracts from bovine parathyroid glands inhibited platelet aggregation, suggesting other constituents were responsible.
    • Platelet aggregation in patients with primary hyperparathyroidism was normal and unaffected by surgery.

    Conclusions:

    • Parathyroid hormone (PTH) is unlikely to be a major uremic toxin responsible for platelet dysfunction.
    • The inhibitory effect of parathyroid gland extracts on platelet aggregation is likely due to non-PTH components.